Archive for December, 2003

h1

107279987937751585

December 30, 2003

A Happy Pill for Some Biotechs
Analysts predict 2003’s rally will continue, with the winners changing to include a few blue-chip names and select up-and-comers.

Advertisements
h1

107279980233861227

December 30, 2003

Biotech: A Coming Boom — or Bust?
Two industry veterans lay out contrasting views about what the sector and its investors can expect over the next 12 months.

h1

107220074852044258

December 23, 2003

Biotech may be poised for “big year”
Biotechnology is poised for a boom year in 2004, wrapping up 2003 with a strong recovery and plenty of reason for optimism, in the forecast of G. Steven Burrill, chief executive officer of the San Francisco-based life sciences merchant bank, Burrill & Co.

h1

107176228631622890

December 18, 2003

Got Life?
Corporate lawyers haven’t had much to celebrate since the Internet bubble burst, but a recent stock market run on life sciences companies is breathing new buoyancy into some practices.

h1

107172880604229265

December 18, 2003

When Patents Persist
What if that patent you’re paying royalties on suddenly gets extended? Have you negotiated the best licensing deal possible?

h1

107158609334708868

December 16, 2003

Amgen’s Cannibalistic Ways
If you don’t think that Amgen is excited about its future, check out what the company is piling on its plate. The biotech giant will be earmarking half of next year’s revenue to launch a $5 billion share buyback.

h1

107151173637091907

December 15, 2003

FDA Chief Eyes Path for Copycat Biotech Drugs
Food and Drug Administration Commissioner Mark McClellan said on Friday it may be justifiable for regulators to approve generic forms of biotech drugs even if they have not been through the same lengthy clinical trials required of the original drugs.